Trial · NCT06207344
The Anesthesia Effects of Dexmedetomidine Combined With Desflurane or Propofol in Lobectomy
NCT06207344, Not applicable, Unknown, The Second Affiliated Hospital of Chongqing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Anesthesia Effects of Dexmedetomidine Combined With Desflurane or Propofol in Lobectomy. Trials, record NCT06207344. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06207344
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Anesthesia Effects of Dexmedetomidine Combined With Desflurane or Propofol in Lobectomy
- NCT number
- NCT06207344
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 120 participants, estimated
- Lead sponsor
- The Second Affiliated Hospital of Chongqing Medical University
- Conditions
- Anesthesia Recovery Period, Postoperative Complications
- Interventions
- Dexmedetomidine and propofol, Dexmedetomidine and desflurane
- First posted
- 2024-01-17
- Last updated
- 2024-03-13
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to open eyes after anesthetics withdrawal | From time of anesthetic withdrawal to the first time of the patient open his or her eyes, assessed up to 2 hour. | The first time to open eyes after anesthetics withdrawal. |
| Secondary | Incidence of delirium | From time of anesthetic withdrawal to the patient leaving the postanesthesia care unit, assessed up to 2 hour. | The Richmond Agitation-Sedation Scale (RASS) will be used to assess the incidence of delirium. RASS is a 10-point scale, with four levels of anxiety or agitation (+1 to +4 \[combative\]), one level to denote a calm and alert state (0), and 5 levels of sedation (-1 to -5) culminating in unarousable (-5). The scores of +2, +3, and +4 are defined as delirium. |
| Secondary | Incidence of nausea and vomiting | From time of anesthetic withdrawal to the patient leaving the postanesthesia care unit, assessed up to 2 hour. | The severity of nausea and vomiting will be evaluated by visual analogue scale (VAS): a 10 cm ruler was used as a scale, one end (0 points) indicated no nausea and vomiting, and the other end was 10 cm, indicating the most severe nausea and vomiting that was unbearable (1\~4 was mild, 5\~6 was moderate, and 7\~10 was severe). |
| Secondary | Pain level | From time of anesthetic withdrawal to the patient leaving the postanesthesia care unit, assessed up to 2 hour. | Numeric Rating Scale will be used to assess the degree of pain. 0\~10 is used to represent different degrees of pain: 0 is no pain, 1\~3 is mild pain (the pain does not affect sleep), 4\~6 is moderate pain (mildly affects sleep), 7\~9 is severe pain (unable to fall asleep or wakes up from sleep), and 10 is severe pain. |
| Secondary | Incidences of other side effects | From time of anesthetic withdrawal to the patient leaving the postanesthesia care unit, assessed up to 2 hour. | Any unquestioned side effects will be recorded, such non-planned intensive care unit transfer, unplanned reoperation, unplanned reintubation, etc. |
| Secondary | Drugs and their dosage | From time of anesthetic withdrawal to the patient leaving the postanesthesia care unit, assessed up to 2 hour. | These drugs and their dosage will be recorded, such as muscle relaxant antagonism, antiemetic drugs, and analgesic drugs. |
| Secondary | QoR-40 scores | Postoperative day 1 and 3. | QoR-40 scores will be used to assess the quality of recovery. The questionnaire consists of five subscales: emotional status (9 items), physical comfort (12 items), psychological support (7 items), physical independence (5 items), and pain (7 items). All the items are rated on a five-point scale ranging from 1 to 5. The initial point and conversion score of each item are calculated. Depending on the question, the best answers may have a score of either 5 or 1. The best answers to positive questions are scored 5, while the best answers to negative questions are assigned the score of 1. The total score of QoR-40 is given by the summation of scores for all items and ranges from 40 to 200. The higher the score, the better is the health status.Citation |
| Secondary | Postoperative pulmonary complications | First 7 postoperative days | The incidence of postoperative pulmonary complications was assessed according to the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) definition. The severity of postoperative pulmonary complications was scored on a 0-5 scale. |
| Secondary | White blood cell count | Postoperative day 1 and 3. | White blood cell count will be used to assess the inflammatory level. |
| Secondary | Neutrophil ratio | Postoperative day 1 and 3. | Neutrophil ratio will be used to assess the inflammatory level. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06207344
GET https://conductscience.org/api/trials/v1/NCT06207344/registered